TVTX - CIK 0001438533
The table below shows Travere Therapeutics, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | $37.78M | -$237.47M | -$280.02M | -$186.29M | -$14.79M | -$42.74M |
| Capital expenditure | - | - | $668.00K | $191.00K | $5.10M | $6.77M |
| Investing cash flow | $27.89M | $99.33M | $55.78M | -$32.55M | -$137.62M | -$61.33M |
| Dividends paid | - | - | - | - | - |
Travere Therapeutics, Inc. reported operating cash flow of $37.78M for fiscal year 2025. That is up 115.9% from -$237.47M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$3.44M (FY 2016) to $37.78M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$33.47M | $139.42M | $218.75M | $117.57M | $231.68M | $127.71M |